TAEUS®

Metabolic disease

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), an asymptomatic precursor to conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH), fibrosis, cirrhosis, and cancer, has traditionally been difficult to identify and monitor. ENDRA is developing technology to change that.

2+ billion people globally

2+ billion people globally

2+ billion people globally with Steatotic Liver Disease (SLD)100M+ in the U.S. alone

5% linked to Metabolic Syndrome

5% linked to Metabolic Syndrome

Liver fat > 5% is linked to Metabolic Syndrome and serious clinical risks

$100B+ direct annual U.S. medical costs

$100B+ direct annual U.S. medical costs

MALSD

MALSD

>90 % of the obese population suffer from MASLD

Arrow Down
Watch the video

Meet Mary

Learn how ENDRA is using ultrasound to help make difficult-to-diagnose diseases easier to find and treat.

WATCH THE VIDEO >

Liver disease is commonplace and largely undiagnosed.

Thankfully, a simple tool is on the horizon. ENDRA’s technology, TAEUS®, offers a solution for measuring liver fat, establishing a key biomarker for metabolic disease management.

“The ability to accurately quantify fat in the liver, at the point of care, with ENDRA’s TAEUS® ultrasound could be revolutionary.”

— Xiang Jing, M.D.

Deputy Chairman, Ultrasound Committee, China Medical Association

TAEUS®’ future potential goes beyond just a single application.

Inclusivity

Obese and fibrotic patients are not excluded from TAEUS® use.

Monitoring

Improves screening for SLD and allows for response to GLP-1 therapies monitoring

Safety

No invasive surgical biopsy, no ionizing radiation, no risky contrast agents

Efficiency

Can be used at the point of patient care, providing answers more quickly and efficiently

The TAEUS product is not yet approved for commercial sale.

See more. Do more. Live better.™

GET IN TOUCH WITH ENDRA >